| Literature DB >> 32545440 |
Francesco Freni1, Francesco Gazia1, Victor Slavutsky2, Enrique Perello Scherdel3, Luis Nicenboim4, Rodrigo Posada5, Daniele Portelli1, Bruno Galletti1, Francesco Galletti1.
Abstract
The aim of the present study was to compare the posterior tympanotomy (PT) technique to the endomeatal approach. The endomeatal approach (EMA) for Cochlear Implant (CI) surgery was performed on 98 patients with procident lateral sinus or a small mastoid cavity, on 103 ears (Group A). Conventional mastoidectomy and PT was performed on the other 104 patients, on 107 ears (Group B). Data on all patients were then collected for the following: intra- and post-operative complications, Tinnitus Handicap Inventory (THI), Vertigo Symptom Scale (VSS), duration of surgery, and postoperative discomfort. The difference in the total number of major and minor complications between the case group and the control group was not statistically significant. There was a statistically significant difference in discomfort between the two groups using the Visual Analogue Scale (VAS), both immediately postsurgery (p = 0.02) and after one month (p = 0.04). The mean duration of surgery was 102 ± 29 min for EMA and 118 ± 15 min for the PT technique (p = 0.008). EMA is a faster technique resulting in reduced postoperative patient discomfort in comparison to the PT method. The experience of the surgeon as well as the correct choice of surgical technique are fundamental to successful outcomes for cochlear implant surgery.Entities:
Keywords: Endomeatal approach; cochlear implant; hearing loss; posterior tympanotomy; tinnitus; without mastoidectomy
Mesh:
Year: 2020 PMID: 32545440 PMCID: PMC7346090 DOI: 10.3390/ijerph17124187
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Study population.
| Features | Group A (EMA) | Group B (PT) | Odds Ratio (95% CI) | |
|---|---|---|---|---|
| Gender | 0.50 | 0.82 (0.47–1.44) | ||
| Male | 52/98 (53%) | 60/104 (57.7%) | ||
| Female | 46/98 (47%) | 44/104 (42.3%) | ||
| Age (years) | 54.35 ± 11.34 | 51.72 ± 8.11 | 0.25 | |
| Deafness Etiology | ||||
| Genetic | 50/98 (51%) | 65/104 (62.5%) | 0.10 | 0.62 (0.35–1.1) |
| Autoimmune | 10/98 (10.2%) | 13/104 (8%) | 0.61 | 0.79 (0.33–1.9) |
| Infection | 15/98 (15.3%) | 12/104 (11.5%) | 0.43 | 1.3 (0.61–3.1) |
| Idiopathic | 23/98 (23.4%) | 14/104 (13.4%) | 0.07 | 1.9 (0.94–4.01) |
| Implant model | ||||
| Med-El | 2/103 (1.9%) | 3/107 (2.8%) | 0.99 | 0.68 (0.11–4.19) |
| Advanced Bionics | 4/103 (3.8%) | 4/107 (3.7%) | 0.99 | 1.04 (0.25–4.27) |
| Oticon Medical | 1/103 (0.9%) | 5/107 (4.6%) | 0.21 | 0.2 (0.02–1.74) |
| Cochlear | 96/103 (93.4%) | 95/107 (88.9%) | 0.33 | 1.73 (0.65–4.58) |
| PTA with aids (dB) | 62.25 ± 5.30 | 59.84 ± 4.26 | 0.28 | |
| WRS with aids (%) | 60.5 ± 3.25 | 58.45 ± 4.65 | 0.35 | |
| VSS presurgery | 0.75 ± 0.28 | 0.88 ± 0.37 | 0.65 | |
| THI presurgery | 35.25 ± 10.32 | 38.15 ± 9.65 | 0.67 | |
| Follow-up (months) | 84.35 ± 15.66 | 82.75 ± 12.4 | 0.55 | |
n—number; %—percentage; M—media; SD—standard deviation; CI—confidence interval; PTA—Pure Tone Average; WRS—Word Recognition Score; THI—Tinnitus Handicap Inventory; VS—Vertigo Symptom Scale.
Intra- and postoperative complications.
| Complications | Group A (EMA) | Group B (PT) | Odds Ratio (95% CI) | |
|---|---|---|---|---|
| Major Complications | 1 (0.9%) | 0 | 0.45 | 3.1 (0.1–78.1) |
| Bacteria Biofilm | 1 (0.9%) | 0 | 0.45 | 3.1 (0.1–78.1) |
| Others | 0 | 0 | ||
| Minor Complications | 3 (2.9%) | 3 (2.8%) | 1 | 1.1 (0.2–5.2) |
| Tympanic perforation | 3 (2.9%) | 0 | 0.11 | 7.4 (0.3–107.7) |
| Subcutaneous emphysema | 0 | 1 (0.9%) | 1 | 0.3 (0.01–8.5) |
| Partial migration of the implant body | 0 | 1 (0.9%) | 1 | 0.3 (0.01–8.5) |
| Facial nerve stimulation | 0 | 1 (0.9%) | 1 | 0.3 (0.01–8.5) |
| Others | 0 | 0 |
n—number; %—percentage; CI—confidence interval
THI, VSS-sf, and VAS discomfort postsurgery and after 1, 3, 6, and 12-month follow-up.
| Follow-Up | Group A (EMA) | Group B (PT) | |
|---|---|---|---|
| THI | |||
| After surgery | 11.8 ± 7.2 | 13.3 ± 8.1 | 0.45 |
| 1 month | 9.6 ± 5.4 | 8.9 ± 4.6 | 0.55 |
| 3 months | 5.4 ± 2.3 | 6.6 ± 2.1 | 0.59 |
| 6 months | 2.9 ± 0.9 | 3.4 ± 1.2 | 0.21 |
| 12 months | 2.1 ± 0.7 | 1.6 ± 0.3 | 0.23 |
| VSS-sf | |||
| After surgery | 21.8 ± 9.4 | 19.7 ± 8.3 | 0.22 |
| 1 month | 4.3 ± 1.2 | 5.8 ± 1.7 | 0.19 |
| 3 months | 1.2 ± 0.2 | 1.7 ± 0.3 | 0.65 |
| 6 months | 0.1 ± 0.02 | 0.1 ± 0.02 | 0.93 |
| 12 months | 0 | 0 | 1 |
| Discomfort VAS | |||
| After surgery | 3.2 ± 1.1 | 5.3 ± 1.3 |
|
| 1 month | 1.9 ± 0.4 | 3.2 ± 0.8 |
|
| 3 months | 0.2 ± 0.05 | 0.5 ± 0.06 | 0.12 |
| 6 months | 0.01 ± 0.002 | 0.01 ± 0.002 | 0.95 |
| 12 months | 0 | 0 | 1 |
M—media; SD—standard deviation; THI—Tinnitus Handicap Inventory; VSS-sf—Vertigo Symptom Scale short form; VAS—Visual Analogue Scale.